Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wuling Powder for Depression in Parkinson's Disease
NCT03195231Phase 4
Key facts
- Status
- Unknown
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Sponsor
- Beijing Hospital
- Modality
- Small Molecules
- Drugs
- wulingshen
- Conditions
- major depressive disorder (MDD)
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Wuling Powder Group with Placebo Group (2 arms). Primary endpoint: Change of depression from baseline at 12 weeks. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Wuling Powder Group
Wuling Powder 3 times a day, 3 pills each time
Placebo Group
Placebo 3 times a day, 3 pills each time
03
Who it enrols
Patients with idiopathic Parkinson's disease (Hoehn-Yahr 1-3) and depression (HAMD >= 13), on stable antiparkinsonian therapy, without severe cognitive impairment or other psychotic symptoms.
04
Endpoints
Primary
Change of depression from baseline
Beyond the preview
Go deeper on NCT03195231.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03195231.